Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ephedra Relative Risk Estimate Stands Despite Data Issues – Researchers

This article was originally published in The Tan Sheet

Executive Summary

Even if 15% of adverse event reports are removed from consideration in the recent Annals of Internal Medicine study on ephedra safety compared with other herbals, "then relative risks we calculated remain exactly the same," the study author states in a letter published in the Sept. 2 issue of the journal

You may also be interested in...

Ephedra Accounts For 64% Of AEs, But Only .82% Of Herbal Sales – Study

Herbal supplements containing ephedra were associated with the majority of adverse events reported in 2001 despite representing a minute fraction of botanical sales that year, according to a recent study

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts